

Recommendations from York and Scarborough Medicines Commissioning Committee 19 November 2014 – NHS Vale of York Clinical Commissioning Group

Drug name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact
Low molecular weight heparins e.g. daltaparin	VTE prophylaxis	Approved	Prevention of VTE in immobile patients. Joint communication between secondary/primary care to be developed.	Amber – specialist initiation	York hospital currently sees 30 patients per month. Costs to primary care for 7 days' supply approx. £5,000/year
Brimonidine topical gel (Mirvaso®)	Symptomatic treatment of facial erythema of rosacea	Not approved	Not commissioned for use.	Black	Nil
Fostair® 100/6 (beclometasone and formoterol) pMDI*	COPD	Approved	Where a corticosteroid/LABA combination is indicated as per COPD pathway	Green	Offers savings compared with Seretide or Symbicort
Fostair® 100/6 (beclometasone and formoterol) Nexthaler breath-actuated dry powder*	Asthma (adults)	Approved	Where a corticosteroid/LABA combination is indicated as per NICE.	Green	May offer savings compared with other devices
MolluDab® (contains 5% potassium hydroxide)	Molluscum contagiosum	Not approved	Not commissioned for use.	Black	Nil
Prostaglandin analogues eye drops	Ocular hypertension	Approved	The following agents are approved: First line: Generic latanoprost 0.005% 2 nd line: Bimotoprost or travaprost <i>For patients unable to have products containing preservatives</i> 1 st line: Latanoprost 50 micrograms/ml p/f eye drops (Monoprost) UDV	Green (for listed products)	Potential savings though use of best value choices

*250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the new NEXThaler device or the pre-existing pressurised metered dose inhaler (pMDI).

Silk garments	Eczema/allergic skin conditions	Not approved	Not commissioned for existing or new patients –insufficient evidence of clinical/cost effectiveness	Black	Nil Spend April 13-April 14 £10,051.00
---------------	---------------------------------	--------------	---	-------	--

*250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the new NEXThaler device or the pre-existing pressurised metered dose inhaler (pMDI).